VDRM (VDRM) Stock Price & Analysis
VDRM (VDRM) rose 0.00% to USD 0 as of June 10, 2026 at 05:04 UTC, according to Nexqual real-time market data.
VDRM last closed at USD 0; the session ranged USD 0–0.01 on volume of 4,099 shares. Market capitalization is $493,485, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 05:04 UTC.
Key Statistics (as of June 10, 2026 at 05:04 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0 – 0.01 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 4,099 shares |
| Market Cap | $493,485 |
| Exchange | PNK |
Technical Analysis (VDRM)
Nexqual's technical model rates VDRM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 05:04 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 53.7 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (VDRM)
Wall Street analysts rate VDRM "None", per Nexqual as of June 10, 2026 at 05:04 UTC.
| Consensus Rating | None |
|---|
Earnings (VDRM)
Source: Nexqual, June 10, 2026 at 05:04 UTC.
Financials & Fundamentals (VDRM)
| Total Revenue | $44,691 |
|---|---|
| Revenue Growth (YoY) | -57.80% |
| Gross Margin | +84.20% |
| Operating Margin | -585.50% |
| Profit Margin | +0.00% |
| Current Ratio | 0.29 |
| Total Cash | $13,082 |
| Total Debt | $423,663 |
| Free Cash Flow | $688,402 |
Source: Nexqual, June 10, 2026 at 05:04 UTC.
Financial Health Score (VDRM)
Nexqual rates VDRM's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:04 UTC.
| Growth | Critical — Revenue -58% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $13K cash, no debt |
| Cash Flow | Strong — FCF $688K, 1540% margin |
| Efficiency | Mixed — No data |
Ownership (VDRM)
| Shares Outstanding | 1.23B |
|---|
Source: Nexqual, June 10, 2026 at 05:04 UTC.
Leadership (VDRM)
VDRM is led by Christopher A Otiko, Founder, Chief Executive Officer and President, per Nexqual as of June 10, 2026 at 05:04 UTC.
| Founder, Chief Executive Officer and President | Christopher A Otiko |
|---|---|
| Chief Financial Officer and Director | Qing Hua Lin (age 44) |
| Corporate Secretary and Director | Zhang Xie (age 46) |
| Medical Director and Member of Advisory Board | Andrew G. Berman M.D., MPH |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HBRM | Herborium Group, Inc. | USD 0 | ▲ 0% |
| USRM | U.S. Stem Cell, Inc. | USD 0 | ▲ 0% |
| WDLF | Decentral Life, Inc. | USD 0 | ▲ 0% |
| MMEX | MMEX Resources Corporation | USD 0 | ▲ 0% |
| GTLL | Global Technologies, Ltd. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:04 UTC. This page is informational and not investment advice.